See more : Nabors Energy Transition Corp. (NETC) Income Statement Analysis – Financial Results
Complete financial analysis of TCR2 Therapeutics Inc. (TCRR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TCR2 Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hefei Department Store Group Co.,Ltd (000417.SZ) Income Statement Analysis – Financial Results
- Celebrity Fashions Limited (CELEBRITY.BO) Income Statement Analysis – Financial Results
- Sprout AI Inc. (BYFMF) Income Statement Analysis – Financial Results
- Universal Security Instruments, Inc. (UUU) Income Statement Analysis – Financial Results
- Henderson Diversified Income Trust plc (HDIV.L) Income Statement Analysis – Financial Results
TCR2 Therapeutics Inc. (TCRR)
About TCR2 Therapeutics Inc.
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 98.64M | 77.24M | 51.98M | 37.49M | 19.67M | 9.57M | 7.67M |
| General & Administrative | 24.44M | 22.50M | 16.72M | 13.89M | 6.78M | 3.61M | 2.26M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.44M | 22.50M | 16.72M | 13.89M | 6.78M | 3.61M | 2.26M |
| Other Expenses | 30.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 123.08M | 99.74M | 68.70M | 51.38M | 26.45M | 13.18M | 9.93M |
| Cost & Expenses | 123.08M | 99.74M | 68.70M | 51.38M | 26.45M | 13.18M | 9.93M |
| Interest Income | 1.94M | 224.00K | 1.74M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 58.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 63.88M | 2.83M | 1.59M | 862.00K | 419.00K | 298.00K | 220.00K |
| EBITDA | -89.62M | -96.92M | -67.11M | -50.52M | -23.83M | -12.77M | -9.70M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -153.50M | -99.74M | -68.70M | -51.38M | -26.45M | -13.18M | -9.93M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.94M | 224.00K | 1.74M | 3.89M | 2.20M | 110.00K | 15.00K |
| Income Before Tax | -151.56M | -99.52M | -66.96M | -47.50M | -24.25M | -13.07M | -9.92M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 261.00K | 289.00K | 161.00K | 102.00K | 2.20M | 110.00K | 15.00K |
| Net Income | -151.82M | -99.81M | -67.12M | -47.60M | -24.25M | -13.07M | -9.92M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.93 | -2.63 | -2.40 | -2.26 | -1.05 | -2.55 | -1.93 |
| EPS Diluted | -3.93 | -2.63 | -2.40 | -2.26 | -1.05 | -2.55 | -1.93 |
| Weighted Avg Shares Out | 38.63M | 37.94M | 27.99M | 21.10M | 23.19M | 5.13M | 5.13M |
| Weighted Avg Shares Out (Dil) | 38.63M | 37.94M | 27.99M | 21.10M | 23.19M | 5.13M | 5.13M |
TCR² Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment of Cholangiocarcinoma
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the U.S. Food and Drug Administration...
TCR² Therapeutics Announces Renowned Translational Medicine Leader Priti Hegde Joins Its Board of Directors
CAMBRIDGE, Mass., Aug. 26, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the appointment of Priti Hegde, Ph.D., to...
TCR² Therapeutics Announces Upcoming Medical Meetings Update
CAMBRIDGE, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that their interim update on the Phase...
TCR² Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced financial results for the second quarter ended...
TCR² Therapeutics Appoints Cell & Gene Therapy Manufacturing Veteran Peter Olagunju as Chief Technical Officer
CAMBRIDGE, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients with solid tumors, today announced the appointment of Peter Olagunju as...
TCR2 Therapeutics - Promising Technology And Upside Potential
TCRR is developing an exciting new TCR-T cell-based therapy that has the potential to deliver improved therapeutic outcomes when compared to CAR-T cell-based therapies.
TCR² Therapeutics to Participate in Two Upcoming Conferences in June
CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that management will participate at two upcoming...
TCR² Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced financial results for the first quarter ended...
TCR² Therapeutics to Present at the Truist Securities Life Sciences Summit
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that management will participate in a fireside...
TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data at AACR Annual Meeting
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that clinical and translational data from the...
Source: https://incomestatements.info
Category: Stock Reports